51 Infos zu Ohad Hammer

8 Aktuelle Nachrichten

Asset Development Well known biotech blogger, Ohad Hammer, works for a venture capital fund, Pontifax, who owns an undisclosed amount of shares.

TargEDys, das innovative Mikrobiom-basierte Lösungen entwickelt, um den Appetit zu regulieren, hat seine Serie A mit 3,5 Millionen Euro vom Unternehmen...

PARIS, April 11, PRNewswire/ -- TargEDys, which develops innovative microbiome-based solutions to regulate the appetite, has extended its Series A by...

Despite bouncing off a 2-year low, biotech is still an unpopular sector and investors are rightfully concerned about its near-term prospects. Recent drug...

4 Profile in Sozialen Netzwerken

ohad hammers berufliches Profil anzeigen LinkedIn ist das weltweit größte berufliche Netzwerk, das Fach- und Führungskräften wie ohad hammer dabei hilft, ...

View ohad hammer's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like ohad hammer discover inside ...

Ohad Hammer, of Pontifax Venture Capital, said: “Delivering drugs to the eye is one of the major challenges in the ophthalmology area.

6 Hobbys & Interessen

mid-cap biotech stocks. He holds a MS in Biotechnology and specializes in ...

Eyevensys Announces Series A Extension Bringing Total Capital Raised to €9 Million

Double_Bagel: New Ohad Hammer Blog http://www.orf-blog.com/clovis-oncology-still-a-long-term-core-holding/ Quote:Portfolio updates We are initiating a...

Ohad Hammer. Follow (920 followers). Send Message. Last month at the ASCO meeting, Curagen (CRGN) presented results for its lead drug, ...

2 Business-Profile

Retrouvez la biographie, l'interview, les coordonnées, les mandats ainsi que toutes les informations concernant Ohad HAMMER sur Verif.com

Life Sciences Business Intelligence Web Portal for European countries

1 Firmen-Mitarbeiter

CEO Tomer Kariv Ran Nussbaum Asaf Shinar Ohad Hammer Silvia Noiman, Ph.D. Brian Schwartz Iyona Rajkomar, MBBS, CFA Momi Karako CEO Tomer Kariv Tomer is the...

5 Allgemeine Veröffentlichungen

Publications Authored by Ohad Hammer

Tumor Escape and Progression under Immune Pressure - A Special Issue published by Hindawi

... Vertreterin von Seventure Partners, - Pierre Déchelotte, Vorsitzender, - Eric de La Fortelle, Vertreter von Seventure Partners, - Ohad Hammer, ...

Is . Biotech portfolio September This entry was posted in Gene therapy and tagged AGTC BMRN DMTX KURA ONCE RGNX by Ohad Hammer.

1 Video- & Audioinhalte

Teile deine Videos mit Freunden, Verwandten oder der ganzen Welt

6 Meinungen & Artikel

Seite 179 der Diskussion 'Biotech Depot - verschiede Werte und Strategien' vom im w:o-Forum 'Biotech'.

Ohad Hammer on September 21, at 3:17 am said: Dan – Amazing, AGN are becoming the new CELG… I still like BLCM, FATE not so ...

cash Leser diskutieren das Thema ARQL FDA Runup Play im grössten Finanzforum der Schweiz.

Ohad Hammer on March 29, at 2:35 am said: Dan (SAGE) – Indeed the pattern is similar to what SAGE has done with SAGE-547.

17 Webfunde aus dem Netz

... Pierre Déchelotte, Chairman; Eric de La Fortelle, representing Seventure Partners; Ohad Hammer, representing Pontifax,; Grégory Lambert, ...

Ohad Hammer. Observer, Partner, Pontifax. Ohad is a Partner at Pontifax, where he is in charge of scouting and project evaluation. In his role at Pontifax, Ohad ...

https://stwity.com/ohadhammer/Medias and Tweets on ohadhammer ( Ohad Hammer ) ' s Twitter Profile. Israel.

Ohad Hammer(@ohadhammer)のツイートやお気に入り、アイコン履歴のページです。過去ログを検索したり、日付ごとにまとめることができます。

Clinical Investigation is a premier publisher of academic, technical and scientific work, Volume 3, Issue 9,

PARÍS, April 11, PRNewswire/ -- TargEDys, que desarrolla soluciones innovadoras basadas en microbioma para regular el apetito, ha ampliado su Serie A en...

Transaction Investors. Pontifax Fund (Lead Investor). Ohad Hammer. Undisclosed. Free Trial. Want unlimited access to the complete database ...

PD: Muy a tener en cuenta el blog de las pharmas de Ohad Hammer...muy recomendable...lastima de mi ingles! Disclosure:I am long THLD ...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

... ophthalmic diseases,” added Ohad Hammer of Pontifax Venture Capital, who joined the Eyevensys board after it closed the Series A round.

Global University Venturing

There is nothing like hearing science told by passionate and talented investigators, and we got a one-two punch on the subject of TIM-3-mediated immunotherapy...

Pontifax is a healthcare-focused venture capital firm with $1.34B million under management seeking transformative, cutting-edge life-sciences technologies in...

TargEDys Extends Series A And Appoints New Board Members - read this article along with other careers information, tips and advice on BioSpace